Literature DB >> 28762375

Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians.

Naga Chalasani1, K Rajender K Reddy2, Robert J Fontana3, Huiman Barnhart4, Jiezhun Gu4, Paul H Hayashi5, Jawad Ahmad6, Andrew Stolz7, Victor Navarro8, Jay H Hoofnagle9.   

Abstract

OBJECTIVES: Idiosyncratic drug induced liver injury (DILI) is a rare but potentially serious liver disorder and a major cause of significant liver injury. Limited data exist on racial differences in DILI incidence, presentation, and course.
METHODS: We compared the causative agents, clinical features, and outcomes of DILI among self-described African-Americans and non-Hispanic whites (Caucasians) enrolled in the DILIN Prospective Study. Individuals with definite, highly likely, or probable DILI enrolled between September 2004 and February 2016 were included in this analysis.
RESULTS: 144 African-Americans and 841 Caucasian patients met the eligibility criteria. Causal medications varied by race: trimethoprim/sulfamethoxazole being the most common cause among African-Americans (7.6 vs. 3.6%) followed by methyldopa (4 vs. <1%), phenytoin (5 vs. <1%), isoniazid (4 vs. 4%), and amoxicillin/clavulanate (4.1 vs. 13.4%). The severity of illness, however, tended to be greater in African-Americans than Caucasians as determined by peak mean bilirubin (14.3 vs. 12.8 mg/dl), INR (1.9 vs. 1.6), and DILIN severity score (3.0 vs. 2.6). The frequency of severe cutaneous reactions was significantly higher in African-Americans (2.1 vs. 0.36% in Caucasians, P=0.048). African-Americans also had higher rates of hospitalization (76.7 vs. 57.6%, P<0.001), liver transplantation or liver related death by 6 months (10.2 vs. 5.8%, P=0.02 after controlling for selected covariates), and chronic DILI (24 vs. 16%, P=0.06).
CONCLUSIONS: The most common DILI causative agents differ between African-Americans and Caucasians. African-Americans are more likely to have severe cutaneous reactions and more severe liver injury leading to worse outcomes, including death and liver transplant.

Entities:  

Mesh:

Year:  2017        PMID: 28762375      PMCID: PMC5667647          DOI: 10.1038/ajg.2017.215

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  26 in total

1.  Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.

Authors:  Robert J Fontana; Paul H Hayashi; Jiezhun Gu; K Rajender Reddy; Huiman Barnhart; Paul B Watkins; Jose Serrano; William M Lee; Naga Chalasani; Andrew Stolz; Timothy Davern; Jayant A Talwakar
Journal:  Gastroenterology       Date:  2014-03-27       Impact factor: 22.682

2.  High-resolution HLA alleles and haplotypes in the United States population.

Authors:  Martin Maiers; Loren Gragert; William Klitz
Journal:  Hum Immunol       Date:  2007-05-24       Impact factor: 2.850

3.  The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA).

Authors:  Temitope Foster; Frank A Anania; Dong Li; Ronit Katz; Matthew Budoff
Journal:  Dig Dis Sci       Date:  2013-04-02       Impact factor: 3.199

4.  Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.

Authors:  C M Nolan; S V Goldberg; S E Buskin
Journal:  JAMA       Date:  1999-03-17       Impact factor: 56.272

5.  Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network.

Authors:  Victor J Navarro; Huiman Barnhart; Herbert L Bonkovsky; Timothy Davern; Robert J Fontana; Lafaine Grant; K Rajender Reddy; Leonard B Seeff; Jose Serrano; Averell H Sherker; Andrew Stolz; Jayant Talwalkar; Maricruz Vega; Raj Vuppalanchi
Journal:  Hepatology       Date:  2014-08-25       Impact factor: 17.425

6.  Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain.

Authors:  M Isabel Lucena; Raúl J Andrade; M Carmen Fernández; Ketevan Pachkoria; Gloria Pelaez; José A Durán; Macarena Villar; Luis Rodrigo; Manuel Romero-Gomez; Ramón Planas; Anabel Barriocanal; Joan Costa; Carlos Guarner; Sonia Blanco; José M Navarro; Fernando Pons; Agustin Castiella; Susana Avila
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

7.  Adverse drug reaction deaths reported in United States vital statistics, 1999-2006.

Authors:  Greene Shepherd; Philip Mohorn; Kristina Yacoub; Dianne Williams May
Journal:  Ann Pharmacother       Date:  2012-01-17       Impact factor: 3.154

8.  Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.

Authors:  Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  Racial differences in nonalcoholic fatty liver disease in the U.S. population.

Authors:  Andrea L C Schneider; Mariana Lazo; Elizabeth Selvin; Jeanne M Clark
Journal:  Obesity (Silver Spring)       Date:  2013-06-11       Impact factor: 5.002

10.  Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations.

Authors:  David E Kleiner; Naga P Chalasani; William M Lee; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Paul H Hayashi; Timothy J Davern; Victor Navarro; Rajender Reddy; Jayant A Talwalkar; Andrew Stolz; Jiezhun Gu; Huiman Barnhart; Jay H Hoofnagle
Journal:  Hepatology       Date:  2013-12-18       Impact factor: 17.425

View more
  12 in total

1.  Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens.

Authors:  Debika Bhattacharya; Amita Gupta; Camlin Tierney; Sharon Huang; Marion G Peters; Tsungai Chipato; Frances Martinson; Neaka Mohtashemi; Dingase Dula; Kathy George; Nahida Chaktoura; Karin L Klingman; Devasena Gnanashanmugam; Judith S Currier; Mary G Fowler
Journal:  Clin Infect Dis       Date:  2021-04-26       Impact factor: 9.079

2.  Development and Validation of a Model Consisting of Comorbidity Burden to Calculate Risk of Death Within 6 Months for Patients With Suspected Drug-Induced Liver Injury.

Authors:  Marwan Ghabril; Jiezhun Gu; Lindsay Yoder; Laura Corbito; Amit Ringel; Christian D Beyer; Raj Vuppalanchi; Huiman Barnhart; Paul H Hayashi; Naga Chalasani
Journal:  Gastroenterology       Date:  2019-07-11       Impact factor: 22.682

Review 3.  Tools for causality assessment in drug-induced liver disease.

Authors:  Hans L Tillmann; Ayako Suzuki; Huiman X Barnhart; Jose Serrano; Don C Rockey
Journal:  Curr Opin Gastroenterol       Date:  2019-05       Impact factor: 3.287

4.  Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries.

Authors:  Harshad Devarbhavi; Marwan Ghabril; Huiman Barnhart; Mallikarjun Patil; Sujata Raj; Jiezhun Gu; Naga Chalasani; Herbert L Bonkovsky
Journal:  Liver Int       Date:  2022-02-15       Impact factor: 8.754

Review 5.  Drug-Induced Liver Injury: Highlights of the Recent Literature.

Authors:  Mark Real; Michele S Barnhill; Cory Higley; Jessica Rosenberg; James H Lewis
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

6.  Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.

Authors:  Naga Chalasani; Herbert L Bonkovsky; Jonathan G Stine; Jiezhun Gu; Huiman Barnhart; Elin Jacobsen; Einar Björnsson; Robert J Fontana; David E Kleiner; Jay H Hoofnagle
Journal:  J Hepatol       Date:  2021-12-22       Impact factor: 25.083

7.  Vanishing bile duct syndrome arising in a patient with HIV infection sequentially treated with trimethoprim/sulfamethoxazole and dapsone.

Authors:  Pradeep Reddy Kathi; Maher Tama; Murray Ehrinpreis; Milton Mutchnick; Maria Westerhoff; Jonathan Mowers; Robert John Fontana
Journal:  Clin J Gastroenterol       Date:  2019-07-17

8.  Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury.

Authors:  Yi-Ju Li; Elizabeth J Phillips; Andrew Dellinger; Paola Nicoletti; Ryan Schutte; Danmeng Li; David A Ostrov; Robert J Fontana; Paul B Watkins; Andrew Stolz; Ann K Daly; Guruprasad P Aithal; Huiman Barnhart; Naga Chalasani
Journal:  Hepatology       Date:  2021-01       Impact factor: 17.298

Review 9.  Drug-Induced Liver Injury in GI Practice.

Authors:  Naemat Sandhu; Victor Navarro
Journal:  Hepatol Commun       Date:  2020-03-13

10.  Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.

Authors:  Herbert L Bonkovsky; Huiman X Barnhart; David M Foureau; Nury Steuerwald; William M Lee; Jiezhun Gu; Robert J Fontana; Paul J Hayashi; Naga Chalasani; Victor M Navarro; Joseph Odin; Andrew Stolz; Paul B Watkins; Jose Serrano
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.